The term Physical AI has started appearing in strategy decks and conference agendas with increasing frequency. The basic idea is straightforward: rather than AI that interprets data on a screen, this is AI embedded in devices, robots and sensors that perceive and act in the real world. In MedTech, that means surgical robots that can handle tissue more precisely, wearables that don't just measure but respond and imaging systems that don't just flag anomalies but guide what happens next.
That is a genuinely significant shift: rather than AI passively analyzing data after the fact, AI is moving into the frontline of care and device operation.
The definitional problem
Start with what Physical AI actually means in MedTech, because it is less clear than the enthusiasm suggests.
Robotic-assisted surgery has existed since the late 1990s. AI-enhanced imaging has been in clinical use for years. Wearables have been monitoring patients outside hospital walls for over a decade. If Physical AI is simply AI applied to physical devices, then it is not new. What would make it genuinely new is a qualitative change in capability: devices that do not just execute instructions but adapt, learn and make bounded decisions in real-time, in uncontrolled environments, with clinical consequences and within regulatory and compliance requirements.
That version of Physical AI is real and emerging, but it is also where the hard questions need to be addressed to determine whether Physical AI can truly transform healthcare. For all the excitement, success demands tackling deeper challenges—technical, regulatory, organizational—that go beyond writing better algorithms.
HCLTech’s The AI Impact Imperatives, 2026 survey of nearly 500 senior executives found that 90% agreed Physical AI will be critical or important to success in the next three years, yet only 19% said their organization has many Physical AI systems in production. This gap between enthusiasm and execution underscores how much heavy lifting remains before Physical AI is routine. The road ahead is less about hype and more about solving four fundamental issues:
1. The medical device is now a learning system
AI-native devices do not freeze at launch. They are designed to learn and improve continually. That means MedTech companies must take lifetime responsibility for their performance. If your surgical robot uses machine learning to refine its technique or your patient monitor adapts to individual patterns, you are effectively committing to manage that device’s education and safety for years after it ships.
The standard response to trust concerns in medical AI is to invoke explainability: give clinicians a confidence score, show them which pixels the model attended to, provide a rationale. This is necessary but insufficient.
The deeper trust problem in Physical AI is about accountability under pressure. Consider a surgical robot operating with partial autonomy during a procedure. The AI recommends a trajectory adjustment. The surgeon has three seconds and an occluded view. What does “human oversight” actually mean in that moment? Who is accountable if the recommendation is followed and the outcome is poor? What does the liability framework say, and is it keeping pace with technology?
In our engineering experience, addressing these challenges means designing clear handoff protocols and fail-safes. For example, when HCLTech co-developed a next-gen robotic surgery platform with a global MedTech leader, our engineers built in logic that forces the robot to yield control to the surgeon whenever conditions deviate from expected patterns—a “safe state” by design. The system also continuously logs its recommendations and actions for post-case review. This approach recognizes a hard truth: introducing an AI that can act in real time means the manufacturer and operator share a new level of accountability, and the device’s design must make that partnership clear to all stakeholders.
CEOs should prepare their organizations to stand behind these learning devices, which means investing in post-market monitoring teams, treating field data as part of the product and being ready to intervene if something goes off track. These are the central design challenges for any Physical AI system with real clinical consequences. The industry needs clearer answers—from regulators, from legal frameworks and from clinical governance bodies—before "supervised autonomy" becomes a meaningful operational standard rather than a reassuring phrase.
2. The end of the two-year product cycle
Traditional MedTech product cycles—often measured in years—are colliding with the realities of AI. In an AI-driven world, waiting 24 months to roll out major improvements is a recipe for obsolescence. The technology may move ahead, or worse, the device may become unsafe as real-world conditions change and your frozen algorithm doesn’t.
To avoid this, MedTech companies need to operate with an almost software-like rhythm of continuous updates, even under regulatory constraints.
The US Food and Drug Administration’s (FDA) Predetermined Change Control Plan (PCCP) framework is one enabler. It creates a pathway for AI systems to evolve after approval without requiring full resubmission for every update—which matters enormously for devices that are supposed to learn and improve. The EU AI Act, alongside the Medical Device Regulation (MDR), adds oversight and classification requirements that will shape how MedTech companies design and document their systems.
Through our verticalized solutions for the MedTech industry, we are helping clients establish AI-native development pipelines that integrate simulation environments, digital twins, validation automation and traceability controls, enabling faster deployment of compliant Physical AI updates under evolving regulatory frameworks such as PCCP.
To support evolving global regulatory requirements, our Intelligent Regulatory Platform (IRP) helps organizations continuously assess regulatory impacts, manage evidence, maintain submission readiness and track changes across FDA, MDR and emerging AI regulations. Such capabilities become increasingly important as Physical AI systems evolve throughout their operational life.
In practice, our engineering teams have helped clients design modular AI algorithms and validation pipelines that can be refreshed quickly within a PCCP framework—moving from multi-year update cycles to biannual or quarterly refreshes.
To support safe iteration, we are deploying purpose-built design and simulation tools so more learning can happen virtually before changes reach clinical environments. This approach is also reflected in The AI Impact Imperatives, 2026 report, where 56% of organizations said they are using purpose-built design and simulation tools. These tools can compress the time needed to validate changes, making it feasible to update devices more frequently while still meeting Six Sigma safety expectations.
In one project, we used a high-fidelity digital twin of a surgical robot, supported by HCLTech’s VisionX solution, to run thousands of virtual procedures overnight, catching corner-case failures before any patient was ever at risk. By front-loading safety validation with such simulations, you can confidently break the two-year cycle without breaking the rules or the device.
Beyond launch, Physical AI devices require continuous performance visibility and service intelligence. Our leading AI platform provides remote monitoring, device observability, predictive service insights and field-performance analytics that help manufacturers proactively manage deployed AI-enabled products and accelerate issue resolution.
Frequent software and AI model updates also demand a more adaptive quality strategy. HCLTech's platform enables automated validation, risk-based testing, traceability and continuous quality assurance for intelligent medical devices, helping manufacturers accelerate release cycles while maintaining compliance and product safety.
The MedTech firms mastering rapid, compliant updates will outpace those clinging to static release schedules. In fact, organizations already deploying Physical AI report faster improvements—The AI Impact Imperatives, 2026 report found that 73% of respondents have reduced R&D costs and 62% report improved production line uptime.
Our verticalized solutions for the MedTech industry provide operational foundations necessary to move Physical AI from pilot programs to trustworthy, scalable and compliant enterprise deployment.
3. Break your silos or miss the revolution
Bringing AI into the physical realm upends the traditional MedTech R&D model. Software engineers cannot pass code to systems engineers while regulatory affairs works in isolation until the end. Hardware, software, data science, quality and clinical experts must work together from day one.
In our experience, this was a critical success factor. When we helped a client develop an AI-powered robotic platform, we co-located multi-disciplinary teams—mechanical engineers with machine learning specialists, surgeons and biomedical scientists with software developers and regulatory experts embedded in the daily stand-ups. This integrated approach—breaking down all the usual silos—shortened development cycles and surfaced potential safety issues early, enabling us to address them proactively before regulatory submission.
Data from The AI Impact Imperatives, 2026 supports this. Companies rolling out Physical AI are moving away from one-size-fits-all technology; 71% prefer fine-tuned, domain-specific models and 56% are using purpose-built design and simulation tools over generic solutions. In practice, that means pulling tribal knowledge from across your organization (and often from partners) into the development process.
The revolution at hand is as much organizational as technological. MedTech leaders should reorganize R&D around integrated systems engineering. The cost of missing this shift is clear: if your AI developers never meaningfully collaborate with your clinical safety team or manufacturing engineers, you won’t create an AI-native device that meets real-world demands.
4. Collaboration is the new competitive advantage
These challenges will not be solved by any single company or technology. They require sustained collaboration across MedTech firms, regulators, payers, clinical institutions and technology providers—not as a footnote, but as the central organizing challenge.
When surveyed in the AI Impact Imperatives, 2026, report, organizations that work with third-party experts on AI initiatives are more than twice as likely to have deployed Physical AI systems to production than those that do not (54% vs. 26%). They are also more likely to report improved safety and risk posture (75% vs. 48%), better resource utilization rates (71% vs. 43%) and increased production line uptime (64% vs. 52%). This is not surprising. Whether through partnerships with AI specialists, joint ventures for data sharing, or pre-competitive consortia to develop industry standards, collaboration can de-risk and accelerate Physical AI in ways solitary efforts cannot match.
We see this firsthand. Our engineering teams frequently partner with device manufacturers, AI startups and cloud providers to tackle challenges together—for example, co-founding a Physical AI lab with a semiconductor leader to advance edge computing in medical-grade scenarios. By combining our domain expertise with specialized partner capabilities, we collectively addressed challenges like ultra-low latency control and on-device learning far faster than any one organization could have done alone.
Collaboration also extends to regulators and healthcare providers. The hard truth is that the ecosystem readiness—liability frameworks, clinical workflows, payer acceptance—moves slower than the tech. If we, as an industry, do not proactively engage and shape those elements, Physical AI will remain stuck in the pilot stage. The most forward-thinking leaders are those who invest time in standards bodies, share de-identified data to build the evidence base and even align with competitors on safety measures. It’s not altruism; it’s enlightened self-interest. If we fail to solve these systemic issues together, none of us fully succeed with Physical AI.
Physical AI will earn its place in MedTech by confronting the hard questions
The technology is increasingly viable: sensors, edge computing and advanced algorithms are all here, but its full potential hinges on solving deep challenges in trust, regulation and integration. By recognizing devices as lifelong learning systems (and gearing up to support them), accelerating controlled updates, smashing internal silos and collaborating externally, MedTech leaders can turn the promise of Physical AI into real performance.
The AI Impact Imperatives, 2026, report confirmed that 90% of executives call Physical AI critical or important for the next three years, yet only 19% of organizations have many Physical AI systems in production. The gap between ambition and execution will not close through hype—it will close by answering the tough questions above. Physical AI can reshape MedTech, but only through pragmatism and partnership in regulated, high-stakes environments.
